NCT06445062 2026-03-13
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
Clinical Trials
28 trialsNCT07079631 2026-03-06
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BioNTech SE
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT06730750 2025-12-15
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07244705 2025-11-24
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Anbogen Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05627635 2025-11-10
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05609370 2025-10-02
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
BeiGene
Phase 1/2 Active not recruiting
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT06922383 2025-04-15
A Clinical Study of Arfolitixorin in Patients With mCRC
Isofol Medical AB
Phase 1/2 Recruiting
NCT03829410 2025-03-04
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
Cardiff Oncology
Phase 1/2 Completed
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT06341309 2024-08-09
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT06434090 2024-05-30
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06373133 2024-04-18
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT06195670 2024-01-08
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT01937715 2016-08-18
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Pfizer
Phase 1/2 Terminated
NCT00625651 2014-04-25
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Amgen
Phase 1/2 Completed
NCT00819754 2014-01-14
IXO+A
Ottawa Hospital Research Institute
Phase 1/2 Terminated
NCT00460603 2013-12-06
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Pfizer
Phase 1/2 Completed
NCT00444041 2013-01-30
ASSO-LM1
Austrian Society Of Surgical Oncology
Phase 1/2 Completed
NCT00784446 2013-01-07
First-line Therapy of Stage IV Colorectal Cancer
University of Cologne
Phase 1/2 Completed
NCT00345761 2010-08-16
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
Chugai Pharmaceutical
Phase 1/2 Completed